Forest Laboratories Completes Acquisition of Cerexa
Alameda, CA - January 11, 2007Forest Laboratories Inc. (NYSE: FRX) has completed its previously announced acquisition of Cerexa Inc. for $480 million plus a potential $100 million milestone payment.
About Forest Laboratories and Its Products
Forest Laboratories (www.frx.com) is a US-based pharmaceutical company dedicated to identifying, developing, and delivering products
that make a positive difference in peoples’ lives. Forest Laboratories’ growing product line includes Lexapro® (escitalopram oxalate),
an SSRI indicated for adults for the internal and maintenance treatment of major depressive disorder and generalized anxiety disorder;
Namenda® (memantine HCl), an N-methyl D-aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe
Alzheimer’s disease; Benicar®* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT® (olmesartan
medoxomil-hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of
hypertension; and Campral®* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
*Benicar is a registered trademark of Daiichi Sankyo Inc., and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of
Merck KGaA, Darmstadt, Germany.
Press Contact:
Cerexa‚ Inc.
Stan Abel
Phone:     510–747–3911
seabel@cerexa.com
Press Contact:
Noonan Russo
David Schull
Phone: 858–546–4810
david.schull@eurorscg.com
| 
